In the organisational context, LEADERSHIP appears more glamorous than the word MANAGEMENT. When it comes to a team whether small or large, we need to realise that the first requirement is to be an effective manager and then a leader. Why so? First and foremost, Managers are responsible for making sure that things are done properly. And while leaders may bring us vision, inspiration and challenge, these things count for nothing without the efficient implementation brought about by good management. To be a great manager, you must have an extensive set of skills, both hard and soft – from planning and delegation to communication and motivation. The skill set is so wide, and hence, for your long-term success, it's wise to analyse your skills in all areas of management – and then to challenge yourself to improve in all of these areas. So, a fundamental question that is unasked, but lingers in the mind often is, Are managers really necessary?

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point

In an earlier article in The Wire Science, I...

How Did Telma Become a 1000+ Cr Brand?

The untold story of Glenmark's phenomenal success in building...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Marketing

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Policies/Sales

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Strategy

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

If Strategy is Commodity, How Can Organisations Ensure Differentiation?

Strategy and strategic planning are perhaps the most hyped-up...

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Digital in Pharma and RoI – What and How to Measure Metrics that Matter

To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them. If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.

Boehringer Ingelheim India focuses on partnerships in NCD management

Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”

Legal Scrutiny

The October 2016 Issue of MedicinMan features articles by K. Hariram, Vivek Hattangadi, Anup Soans and has a special focus on ethics and morals in the healthcare profession. Other topics covered include new product launches, the role of emotions in pharma sales and sales coaching.